The scientific community knows that vascular endothelial growth factor (VEGF) causes increased, vascular permeability, resulting in diabetic macular edema (DME) in the ischemic retina, but how to stop the VEGF drive remains the challenge.
The Diabetic Retinopathy Clinical Research Network’s (DRCR.net) Protocol T—the first head-to-head-to-head comparison among aflibercept (Eylea, Renegeron Pharmaceuticals), ranibizumab (Lucentis, Genentech), and bevacizumab (Avastin, Genentech)—found in its first-year results that all three agents improved vision and reduced edema effectively.
Patients with a history of frequent anti-vascular endothelial growth factor (anti-VEGF) injections for the treatment of age-related macular degeneration (AMD) may not be the best potential candidates for encapsulated cell technology (ECT).
Chronic dry eye disease (DED) affects more than 25 million people and to date the only pharmacologic therapies are topical or involve punctal plugs. Results from two studies wth a neurostimulator indicate there may be a new pathway to upregulate the body’s tear system.
When it comes to finding new treatments for diabetic macular edema (DME), there is no shortage of promising targets, said Peter A. Campochiaro, MD. He presented an overview of future compounds with various mechanisms of action that may change how clinicians treat DME.
Perhaps none so much as Graham D. Barrett, MD, a “pre-eminent expert in cataract and refractive surgery, and corneal and anterior segment disorders and surgery,” who was chosen to deliver the 2016 Charles D. Kelman Innovator Lecture at this year’s American Society of Cataract and Refractive Surgery meeting.
There may be a correlation between a person’s preferred sleep position and the health of his or her meibomian glands, said David Alevi, MD. Speaking at ASCRS 2016, Dr. Alevi said meibomian gland dysfunction (MGD) is thought to be a leading cause of dry eye, and often presents with similar symptoms.
NASA’s Vision Impairment and Intracranial Pressure (VIIP) project was started after NASA realized many astronauts return from space with vision problems, and these problems may last for years after mission completion.